Bellevue Group AG Has $11.57 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Bellevue Group AG grew its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 5.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 308,311 shares of the company’s stock after acquiring an additional 15,138 shares during the period. Bellevue Group AG owned 0.26% of 10x Genomics worth $11,571,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock valued at $26,000 after buying an additional 371 shares in the last quarter. Covestor Ltd increased its stake in 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after acquiring an additional 873 shares during the last quarter. UMB Bank n.a. grew its stake in shares of 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after buying an additional 266 shares during the last quarter. Harvest Fund Management Co. Ltd bought a new stake in shares of 10x Genomics during the fourth quarter worth $66,000. Finally, Headlands Technologies LLC bought a new stake in shares of 10x Genomics during the first quarter worth $71,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Serge Saxonov sold 4,877 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the sale, the chief executive officer now directly owns 889,641 shares of the company’s stock, valued at $21,618,276.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Justin J. Mcanear sold 2,936 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total transaction of $71,344.80. Following the completion of the sale, the chief financial officer now directly owns 146,203 shares of the company’s stock, valued at $3,552,732.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 4,877 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total transaction of $118,511.10. Following the completion of the sale, the chief executive officer now directly owns 889,641 shares of the company’s stock, valued at $21,618,276.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,900 shares of company stock worth $289,170. Company insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG traded up $0.30 during trading on Friday, hitting $20.22. 1,648,334 shares of the company traded hands, compared to its average volume of 2,496,850. The business’s fifty day moving average is $20.21 and its 200 day moving average is $31.77. 10x Genomics, Inc. has a fifty-two week low of $15.28 and a fifty-two week high of $63.57. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -9.07 and a beta of 1.84.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). 10x Genomics had a negative net margin of 42.20% and a negative return on equity of 30.85%. The firm had revenue of $141.01 million for the quarter, compared to analyst estimates of $142.24 million. During the same quarter in the prior year, the business earned ($0.44) earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, analysts predict that 10x Genomics, Inc. will post -1.53 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on TXG shares. Bank of America decreased their target price on shares of 10x Genomics from $36.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, July 18th. The Goldman Sachs Group decreased their target price on shares of 10x Genomics from $26.00 to $16.00 and set a “sell” rating on the stock in a research note on Tuesday, July 9th. UBS Group decreased their target price on shares of 10x Genomics from $52.00 to $30.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. JPMorgan Chase & Co. cut shares of 10x Genomics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $40.00 to $20.00 in a research note on Thursday, July 18th. Finally, Barclays decreased their target price on shares of 10x Genomics from $36.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, June 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $36.29.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.